Rasby (Rasburicase 1.5mg Injection) is a prescription medication used to treat high levels of uric acid in the blood (hyperuricemia) in patients with cancer.
Composition:
Each 1.5 mL injection of Rasby contains 1.5mg of rasburicase, a recombinant urate oxidase enzyme. The injectable solution is sterile and preservative-free.
Mechanism of Action:
Rasby works by converting uric acid into allantoin, a compound that is easily excreted by the kidneys. This helps to reduce the levels of uric acid in the blood and alleviate symptoms associated with hyperuricemia.
Dosage:
The recommended dosage of Rasby is 0.2 mg/kg administered intravenously once daily for up to 7 days. The injection should be given slowly over 30 minutes.
Uses:
Rasby is indicated for the treatment of:
- Hyperuricemia in patients with cancer, particularly those with leukemia, lymphoma, or solid tumors
- Prevention of tumor lysis syndrome (TLS) in patients with cancer
Side Effects:
Common side effects of Rasby include:
- Injection site reactions (pain, swelling, redness)
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Rash
- Fever
Rare but serious side effects include:
- Anaphylaxis (severe allergic reaction)
- Hypersensitivity reactions (including angioedema and bronchospasm)
- Hemolytic anemia (blood disorder)
- Thrombocytopenia (low platelet count)
Recommendation:
Rasby should be used under the guidance of a healthcare professional. Patients should be monitored regularly for changes in their uric acid levels and for signs of allergic reactions or other adverse events.
Important Note:
Rasby is not recommended for use in:
- Patients with severe kidney disease or end-stage renal disease
- Patients with severe liver disease or liver failure
- Patients with a history of allergy or hypersensitivity to rasburicase
- Pregnant or breastfeeding women
Additionally, patients with a history of anemia or bleeding disorders should be closely monitored while using Rasby.
Reviews
There are no reviews yet.